A snapshot of chemoresistance to PARP inhibitors
- 4 November 2011
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 33 (1) , 42-48
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Harnessing synthetic lethal interactions in anticancer drug discoveryNature Reviews Drug Discovery, 2011
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cellsProceedings of the National Academy of Sciences, 2011
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast CancerNew England Journal of Medicine, 2011
- The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical TargetsMolecular Cell, 2010
- PARP inhibition: PARP1 and beyondNature Reviews Cancer, 2010
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences, 2008
- Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulationCurrent Opinion in Cell Biology, 2008
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005
- The PARP superfamilyBioEssays, 2004